BridgeBio Pharma Inc (BBIO) Implied Volatility Current

Tracking BBIO implied volatility helps you identify when options premiums on BridgeBio Pharma Inc are historically cheap or expensive, and where the best trades are hiding. BridgeBio Pharma Inc implied volatility reflects the market's expectation of future price movement: when BBIO IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor BridgeBio Pharma Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For BBIO, tracking metrics like BBIO IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on BBIO signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where BBIO implied volatility sits today versus where it has been. Our scanner ranks BridgeBio Pharma Inc implied volatility against its historical range, surfaces extremes in BBIO IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether BridgeBio Pharma Inc IV is rich or cheap — measure it, then act on it.